Theraly Pharmaceuticals
Baltimore
About Theraly Pharmaceuticals
Theraly is a product focused pharmaceutical company with a goal to efficiently generate medically important, stable, and long-acting therapies. Theraly enables products using its proprietary platform technology that can empower short-acting peptides and proteins by dramatically increasing their half-lives while maintaining potency. Their lead program is a preclinical stage product in development for organ fibrosis. TLY012, has shown therapeutic efficacy in a number of pre-clinical models of organ fibrosis, autoimmune/inflammatory conditions, and in oncology.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $200.0K
- Funding stage: Seed
- Last round: Seed (Mar 2018)
- Website: theraly.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/theraly-pharmaceuticals-181204 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.